Sonia Iyer,Shuang Zhang,Simge Yucel,Heiko Horn,Sean G Smith,Ferenc Reinhardt,Esmee Hoefsmit,Bimarzhan Assatova,Julia Casado,Marie-Charlotte Meinsohn,M Inmaculada Barrasa,George W Bell,Fernando Pérez-Villatoro,Kaisa Huhtinen,Johanna Hynninen,Jaana Oikkonen,Pamoda M Galhenage,Shailja Pathania,Paula T Hammond,Benjamin G Neel,Anniina Farkkila,David Pépin,Robert A Weinberg,Sean G. Smith,M. Inmaculada Barrasa,George W. Bell,Pamoda M. Galhenage,Paula T. Hammond,Benjamin G. Neel,Robert A. Weinberg

Abstract:Despite advances in immuno-oncology, the relationship between tumor genotypes and response to immunotherapy remains poorly understood, particularly in high-grade serous tubo-ovarian carcinomas (HGSC). We developed a series of mouse models that carry genotypes of human HGSCs and grow in syngeneic immunocompetent hosts to address this gap. We transformed murine-fallopian tube epithelial cells to phenocopy homologous recombination-deficient tumors through a combined loss of Trp53, Brca1, Pten, and Nf1 and overexpression of Myc and Trp53 R172H, which was contrasted with an identical model carrying wild-type Brca1. For homologous recombination-proficient tumors, we constructed genotypes combining loss of Trp53 and overexpression of Ccne1, Akt2, and Trp53 R172H, and driven by KRAS G12V or Brd4 or Smarca4 overexpression. These lines form tumors recapitulating human disease, including genotype-driven responses to treatment, and enabled us to identify follistatin as a driver of resistance to checkpoint inhibitors. These data provide proof of concept that our models can identify new immunotherapy targets in HGSC. SIGNIFICANCE: We engineered a panel of murine fallopian tube epithelial cells bearing mutations typical of HGSC and capable of forming tumors in syngeneic immunocompetent hosts. These models recapitulate tumor microenvironments and drug responses characteristic of human disease. In a Ccne1-overexpressing model, immune-checkpoint resistance was driven by follistatin.This article is highlighted in the In This Issue feature, p. 211.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is that in high - grade serous ovarian carcinomas (HGSC), the relationship between tumor genotypes and immunotherapy responses has not been fully understood, especially in the case of limited responses to immune checkpoint blockade (ICB) therapy. To fill this knowledge gap, researchers have developed a series of mouse models carrying human HGSC genotypes and grown them in syngeneic immunocompetent hosts to better mimic the human disease state, thereby discovering new combined immunotherapy methods. Specifically, researchers introduced common mutation combinations related to human HGSC into mouse fallopian tube epithelial cells through CRISPR/Cas9 technology, including homologous recombination deficiency (HRD) and homologous recombination - proficient (HR Proficient) tumor models. These models can form tumors similar to human diseases and exhibit genotype - driven drug - response characteristics, allowing researchers to identify follistatin, a key factor leading to resistance to immune checkpoint inhibitors. These models provide a proof - of - concept for the discovery of new immunotherapy targets and are helpful for improving the treatment outcomes of ovarian cancer patients.

Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy